financetom
Business
financetom
/
Business
/
US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial
Oct 4, 2024 6:12 PM

Oct 4 (Reuters) - The U.S. Food and Drug Administration

has placed a clinical hold on Kezar Life Sciences' ( KZR ) trial

of experimental drug for lupus, the company said on Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says
Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says
Jul 16, 2024
11:27 AM EDT, 07/16/2024 (MT Newswires) -- Biogen (BIIB) needs to acquire additional revenue-generating assets for the turnaround to complete, Wedbush said in a Tuesday note to clients. The company has indicated capacity for $8 billion to $10 billion additional transactions over the next two years, according to the note. Potential acquisitions were narrowed down to Pharvaris (PHVS), Viridian Therapeutics...
3M Invests in Ohmium International
3M Invests in Ohmium International
Jul 16, 2024
11:30 AM EDT, 07/16/2024 (MT Newswires) -- 3M ( MMM ) said Tuesday it has invested in Ohmium International, which develops electrolyzer systems used in green hydrogen production. The industrial giant said the deal is part of its commitment to developing technologies for a low-carbon economy and decarbonizing its operations further. Financial terms of the investment were not disclosed. Price:...
Progressive's quarterly profit surges on strong demand for auto insurance policies
Progressive's quarterly profit surges on strong demand for auto insurance policies
Jul 16, 2024
(Reuters) - Insurer Progressive Corp posted a more than fourfold jump in its second-quarter profit on Tuesday, driven by strong demand for its personal auto insurance policies, sending its shares up 3.5% in premarket trading. Rising wages and a strong labor market encouraged customers to revive their spending on auto insurance, one of Progressive's core businesses. The company has also...
National Bank Trims AirBoss of America Target to $5.75 in Q2 Preview
National Bank Trims AirBoss of America Target to $5.75 in Q2 Preview
Jul 16, 2024
11:22 AM EDT, 07/16/2024 (MT Newswires) -- National Bank has trimmed its one year target on AirBoss of America ( ABSSF ) to $5.75, from $6.25, but kept its Sector Perform rating. Analyst Ahmed Abdullah has tempered estimates as macro factors continue to drive softness across some customer segments for both AirBoss Rubber Solutions (ARS) and AirBoss Manufactured Products (AMP)....
Copyright 2023-2026 - www.financetom.com All Rights Reserved